STAT13d
Editas, after slow start, outlines plan to catch other CRISPR companies
"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...
GlobalData on MSN5d
Intellia doses first subject in trial of NTLA-2002 for hereditary angioedema
Intellia Therapeutics has dosed the first subject in the Phase III trial of NTLA-2002, to treat hereditary angioedema (HAE).
PharmiWeb6d
Advancing the development of CRISPR platform technologies
Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential
Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...
CrisprBits opens Research and Innovation Centre for CRISPR Gene Editing and Diagnostics in Bengaluru
PRNewswire Bengaluru Karnataka [India] January 16 Bengaluru-based biotechnology startup CrisprBits Private Limited has ...
Insider Monkey on MSN11d
CRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside Potential
In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ ... have significant upside potential ...
Promising Developments and Strategic Partnerships Drive Crispr Therapeutics’ Growth Potential
William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating on January 14.Stay Ahead of the ...